Acquisition of a controlling stake in Emory Genetics Laboratory
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the successful closing of the transaction to acquire a 75% stake in Emory Genetics Laboratory ("EGL") from Emory University's School of Medicine, as communicated on the 29th of June, 2015.
EGL is renowned for testing rare genetic disorders, and leads the industry in gene panels including cancer testing and exome sequencing to aid diagnosis, prognosis, management and targeted drug therapy (e.g., personalized medicine), in addition to expanded carrier testing capabilities. The lab serves over 400 institutional clients (hospitals and other commercial laboratories) across the US, and expects to generate revenues in excess of US$ 15m for 2015. Henceforth, the company will be known as EGL Genetic Diagnostics, LLC, a joint venture company of Eurofins and Emory University.